Brean Murray Initiates Coverage on Molecular Insight Pharmaceuticals (MIPI) with a Buy
More News related to MIPI
- Molecular Insight Pharmaceuticals Announces Changes to Board
- Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference
- Molecular Insight Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009
- Molecular Insight Pharma (MIPI) Executes 10-Year Agreement to Supply Onalta to BioMedica Life Sciences
Brean Murray initiates coverage on Molecular Insight Pharmaceuticals (Nasdaq: MIPI) with a Buy. Price target $11.
To see more analyst ratings on MIPI Click Here.
Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States.
Related Categories
New CoverageStocks Mentioned
-0.40Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
